search
Back to results

Low Dose Apomorphine and Parkinsonism

Primary Purpose

Parkinson's Disease

Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
apomorphine
Sponsored by
Oregon Health and Science University
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson's Disease focused on measuring Parkinson's disease, PD, apomorphine

Eligibility Criteria

35 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have idiopathic Parkinson's disease treated with levodopa and experiencing motor fluctuations
  • Response to levodopa had to be documented by a 10 percent increase in finger or foot tapping speed

Exclusion Criteria:

  • Clinically significant cardiovascular, cerebrovascular, hepatic and renal diseases
  • Psychosis
  • Allergy to apomorphine or 5ht3 inhibitors
  • Prolonged qt interval
  • Pregnancy/breast-feeding
  • Hemodynamic instability
  • Severe nausea
  • Alcohol/drug abuse
  • Other unstable medical conditions

Sites / Locations

  • Department of Neurology, Oregon Health and Science University, Mail Code OP32, 3181 SW Sam Jackson Park Road

Outcomes

Primary Outcome Measures

Effects on parkinsonism measured with finger and foot tapping speed

Secondary Outcome Measures

Full Information

First Posted
May 10, 2007
Last Updated
November 27, 2018
Sponsor
Oregon Health and Science University
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00472355
Brief Title
Low Dose Apomorphine and Parkinsonism
Official Title
Does Presynaptic Dopamine Receptor Stimulation Transiently Worsen Parkinsonism?
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Withdrawn
Why Stopped
Insufficient study materials
Study Start Date
October 2005 (Actual)
Primary Completion Date
May 2007 (Actual)
Study Completion Date
May 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oregon Health and Science University
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine if low doses of apomorphine worsen the motor symptoms of Parkinson's disease.
Detailed Description
The goal of the study is to learn why some people with Parkinson's disease (PD) get worse right after taking PD medication such as carbidopa/levodopa or as the medication is wearing off. In this study scientists will determine if apomorphine, a drug used to treat symptoms of PD, will worsen the motor symptoms of people with PD when low doses of the drug are given as a continuous subcutaneous infusion. A continuous subcutaneous infusion means the drug is administered continuously through a small needle placed under the skin. Apomorphine, a PD drug that works similar to carbidopa/levodopa, will be used in this study because it is faster-acting and has a more brief effect than carbidopa/levodopa. After the initial screening, participants will enter a 3-day treatment phase during which they will receive in random order low dose apomorphine, high dose apomorphine, or placebo (inactive substance). All participants will receive the study drug for 2 of the days at 2 different doses (low and high) and a placebo for 1 day. During the 3 days participants will provide blood samples and have their hearts monitored. Parkinsonism will be monitored each day by speed of finger tapping, foot tapping and walking as well as tremor and dyskinesia scores. Duration of the study for participants is approximately 4 to 5 days including 1-2 outpatient visits and a 3-day inpatient hospital stay.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease
Keywords
Parkinson's disease, PD, apomorphine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
apomorphine
Primary Outcome Measure Information:
Title
Effects on parkinsonism measured with finger and foot tapping speed

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have idiopathic Parkinson's disease treated with levodopa and experiencing motor fluctuations Response to levodopa had to be documented by a 10 percent increase in finger or foot tapping speed Exclusion Criteria: Clinically significant cardiovascular, cerebrovascular, hepatic and renal diseases Psychosis Allergy to apomorphine or 5ht3 inhibitors Prolonged qt interval Pregnancy/breast-feeding Hemodynamic instability Severe nausea Alcohol/drug abuse Other unstable medical conditions
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John G. Nutt, MD
Organizational Affiliation
Professor of Neurology, Oregon Health and Science University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Steven Gunzler, MD
Organizational Affiliation
Fellow and Clinical Instructor in Neurology, Oregon Health and Science University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Neurology, Oregon Health and Science University, Mail Code OP32, 3181 SW Sam Jackson Park Road
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
18268187
Citation
Gunzler SA, Koudelka C, Carlson NE, Pavel M, Nutt JG. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. Arch Neurol. 2008 Feb;65(2):193-8. doi: 10.1001/archneurol.2007.58.
Results Reference
derived

Learn more about this trial

Low Dose Apomorphine and Parkinsonism

We'll reach out to this number within 24 hrs